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The early bactericidal activity of antituberculosis agents is usually determined bymeasuring the reduction of the sputummyco-
bacterial load over time on solid agar medium or in liquid culture. This study investigated the value of a quantitative PCR assay
for early bactericidal activity determination. Groups of 15 patients were treated with 6 different antituberculosis agents or regi-
mens. Patients collected sputum for 16 h overnight at baseline and at days 7 and 14 after treatment initiation. We determined the
sputum bacterial load by CFU counting (log CFU/ml sputum, reported as mean standard deviation [SD]), time to culture posi-
tivity (TTP, in hours [mean SD]) in liquid culture, and Xpert MTB/RIF cycle thresholds (CT, n [mean SD]). The ability to
discriminate treatment effects between groups was analyzed with one-way analysis of variance (ANOVA). All measurements
showed a decrease in bacterial load frommean baseline (log CFU, 5.72 1.00; TTP, 116.0 47.6; CT, 19.3 3.88) to day 7 (log
CFU,0.26 1.23, P 0.2112; TTP, 35.5 59.3, P 0.0002; CT, 0.55 3.07, P 0.6030) and day 14 (log CFU,0.55 1.24,
P 0.0006; TTP, 54.8 86.8, P< 0.0001; CT, 2.06 4.37, P 0.0020). The best discrimination between group effects was found
with TTP at day 7 and day 14 (F 9.012, P< 0.0001, and F 11.580, P< 0.0001), followed by log CFU (F 4.135, P 0.0024,
and F 7.277, P< 0.0001). CTwas not significantly discriminative (F 1.995, P 0.091, and F 1.203, P 0.316, respectively).
Culture-based methods are superior to PCR for the quantification of early antituberculosis treatment effects in sputum.
Several novel antituberculosis drugs and regimens are currentlyunder clinical investigation. The first step in their evaluation is
the measurement of early bactericidal activity (EBA) in sputum
over up to 2 weeks of treatment in smear-positive, treatment-
naive pulmonary tuberculosis patients. The EBA is commonly de-
fined as the mean daily decrease in CFU counted on agar plates
(log CFU) perml of expectorated sputum (1, 2). Alternatively, the
change in time to culture positivity (TTP) in broth culture can be
measured in themycobacterial growth indicator tube (MGIT) sys-
tem (Becton, Dickinson, Sparks, MD) (3). This is based on the
inverse relationship of the time a culture requires to develop a
critical measure of metabolic activity to the number of viable bac-
teria initially inoculated into the system. TTP in semiautomated
liquid culture has been shown to correlate well withCFU counting
in the first 2 weeks of treatment (3–5).
The Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA) is
a new nucleic acid amplification test (NAAT) detectingM. tuber-
culosis complex on sputum specimens with real-time PCR. Xpert
is rapid (less than 1 h of hands-on time), standardized, and easy to
use (6, 7). Its sensitivity to detect M. tuberculosis in sputum of
untreated patients suspected of having tuberculosis in high-bur-
den countries is 98% for AFB-positive samples and 72% for AFB-
negative specimens with an overall specificity of99% (8). Xpert
is able to detect as few as 100 organisms per ml in vitro suspension
(9). It is less well known that Xpert also provides a semiquantita-
tivemeasurement based on the number of PCR cycles required for
detection of a critical amount of DNA (cycle threshold [CT]). It
was repeatedly demonstrated on spiked samples and sputum sam-
ples collected from untreated tuberculosis patients that the quan-
titative CT readouts from Xpert correlate with (semi)quantitative
results of conventional microbiological tests such as smear mi-
croscopy grade, liquid culture TTP, and solid-culture CFU counts
(9–13).
As a platform for quantifyingM. tuberculosis in sputum, Xpert
could make EBA studies less costly, more reproducible, and tech-
nically more accessible if the change in CT is a reliable measure of
treatment effects. However, it is unclear howDNA load correlates
with culture-based quantification of viable bacteria in patients
being treated for tuberculosis. To investigate this question, we
performed a prospective study to compare the ability of log CFU,
TTP, and XpertCT to monitor and distinguish between treatment
effects in a 14-day EBA study with 6 parallel groups receiving
different antituberculosis treatments.
MATERIALS AND METHODS
Sample collection and ethics. Sputum samples were collected during a
14-day early bactericidal activity study from untreated adult pulmonary
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tuberculosis patients. Participants were required to be smear positive
(1; WHO/IUATLD scale [14]) and free of severe comorbidities. HIV-
positive patients with a CD4 count of250/l and those on antiretroviral
therapy were excluded. From December 2010 until August 2011, 90 pa-
tients (59%male; 10% HIV positive; median age, 30.4 years) were hospi-
talized at one of two centers in Cape Town, South Africa (University of
Cape Town Lung Institute, Mowbray; Task Applied Science, Intercare,
Durbanville) and randomized to one of six equally sized groups that were
treated with different dosages and/or combinations of two antituberculo-
sis agents. All patients’ isolates were susceptible to the treatment given.
Spontaneously expectorated sputum was collected for 16 h overnight,
refrigerated after collection, and transported to the central study labora-
tory (Centre of Clinical Tuberculosis Research, Department of Biomedi-
cal Sciences, Stellenbosch University). Specimens were allowed to warm
up to room temperature before homogenization for 30 min with a mag-
netic stirrer and processing. The institutional ethical committees and the
Medicines Control Council (MCC) granted approval for the main study
and this substudy.
Determination of log CFU. A maximum of 10 ml of homogenized
sputum was digested by addition of an equal volume of 0.1% dithiothre-
itol (Sputasol; Oxoid, Cambridge, United Kingdom) for 20 min. Sterile
saline (0.85%) containing 0.01% Tween was used to generate 10-fold
serial dilutions. A volume of 100 l of every dilution was incubated on
each half of two selective agar plates containing Middlebrook 7H11 agar
enriched with Middlebrook OADC (oleic acid-albumin-dextrose-cata-
lase; Becton,Dickinson) and Selectatab (Mast; Bootle,Merseyside,United
Kingdom) containing polymyxin B sulfate (200,000 units/liter), ampho-
tericin B (10 mg/liter), ticarcillin (100 mg/liter), and trimethoprim (10
mg/liter). The plates were incubated at 37°C for 3 to 4 weeks before colo-
nies were counted on the dilution that yielded between 20 and 200 colo-
nies. These data were log transformed to provide log CFU.
Determination of TTP. Fiveml of digested sputumwasmixedwith an
equal volume of 2% NaOH (BBL Mycoprep; Becton, Dickinson) and
decontaminated for 20 min at room temperature. This mixture was neu-
tralized by addition of sterile phosphate-buffered saline (PBS, pH 6.8;
Becton, Dickinson) to a final volume of 45 ml and centrifuged for 15 min
at 3,000 g and 4°C. The supernatant was discarded and the pellet resus-
pendedwith PBS to a final volume of 2ml. TwoMGITs for each specimen
were prepared by addition of 0.8 ml PANTA (polymyxin B, amphotericin
B, nalidixic acid, trimethoprim, and azlocillin) mixed with OADC (Bec-
ton, Dickinson). Each MGIT was inoculated with 0.5 ml of resuspended
pellet and incubated at 37°C in a Bactec MGIT960 instrument. Cultures
that were flagged as positive were tested for contamination by placing one
drop on a blood agar plate (NHLS, Cape Town, South Africa) and incu-
bating at 37°C for 48 h. The presence of acid-fast bacilli (AFB) in positive
liquid culture was confirmed by Ziehl-Neelsen staining and microscopy;
only TTPs from AFB positive and noncontaminated cultures were used
for analysis.
Xpert MTB/RIF assay. An aliquot of digested sputum sample (1 to 2
ml) was frozen at80°C at the time of culture processing. After thawing,
the specimen was resuspended by vortexing, and 1ml was used according
to the instructions of the manufacturer. Briefly, the diluted sample was
mixedwith 2ml ofXpert sample reagent, inverted 10 times, and incubated
for 15 min at room temperature; inversion was repeated after the first 8
min. Thismixturewas then transferred into anXpert cartridge and loaded
into the GeneXpert instrument, which conducts all necessary steps auto-
matically using GeneXpert Dx software (version 4.0; Cepheid). The soft-
ware reports results as CTs, which represent the number of PCR cycles
needed to reach a detection threshold; the CT of probe B was used for all
analyses according to previously published data (6).
Analysis plan. From the sputum samples available from the EBA
study, we prospectively selected the two baseline samples collected on the
days directly preceding the treatment initiation and those collected after 7
and 14 days of treatment, when we expected treatment effects to emerge.
We analyzed the data in a stepwise fashion. First, we studied the baseline
samples to gain an impression of the variation of the measurements with-
out treatment effects. Second, individual values were plotted against one
another and inspected for correlation. Next, we examined the correlation
of individual treatment activities for all measurements. Finally, we quan-
tified the treatment effects and the respective ability of the measurements
to differentiate between treatment groups by comparing variation within
the groups to the variation between the groups for the periods from 0 to 7
days and 0 to 14 days.
Statistical methods. The group sample size of 15 patients and study
duration of 14 days were predetermined by the parent EBA study. Corre-
lations between the methods of detection were quantified with the Spear-
man rank sum test. Treatment activity was calculated as the arithmetic
difference between the means of the baseline values (also termed day 0
values) and the values obtained after 7 or 14 days, first for each individual
and then as an average to obtain a group result. The significance of treat-
ment effects within groups from day 0 to 7 or day 0 to 14 was determined
by Student’s t test. Variance within groups and between groups was com-
pared with F statistics (one-way analysis of variance [ANOVA]). The
larger the F statistic is, the better the chance that a measurement can
differentiate group effects. A P value of0.05 was considered statistically
significant.
RESULTS
Log CFU, TTP, andCT.Out of a possible 360 values, 304 log CFU
(84.4%), 341 TTP (94.7%), and 317 CT (88.1%) results were ob-
tained. Themissing values were due to contamination, no growth,
no sample being received, or invalid results. There was no signif-
icant difference between groups regarding the proportions of
available data or the magnitude of the mean baseline values. The
day-to-day variance estimated using the baseline values within









































FIG 1 Individual log CFU, TTP, and CT values are shown for all patients and time points combined. Rho values were calculated by the Spearman rank sum test
for log CFU versus TTP (rho0.613; P 0.0001), log CFU versus CT (rho0.547; P 0.0001), and TTP versus CT (rho 0.632; P 0.0001).
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subjects was compared with the total baseline variance to give
ratios of 0.1621/0.9853 (0.165) for log CFU, 748.7/3448.5 (0.220)
for TTP, and 12.25/6.94 (0.567) for CT. While 16.5% and 22% are
similar, the value of 56.7% for CT suggests a larger day-to-day
variability and smaller between-subject variability for CT than for
the culture-based measurements, log CFU count and TTP. Indi-
vidual log CFU, TTP, andCT values weremoderately correlated at
baseline, day 7, and day 14 and are illustrated in Fig. 1.
Treatment effects measured with log CFU, TTP, and CT. In-
dividual treatment effects were strongly correlated between log
CFU and TTP; log CFU and CT and TTP and CT were moderately
correlated (Fig. 2). All three measurements showed an overall de-
crease from baseline, which was significant for TTP at day 7 and
for all threemeasurements at day 14 (Table 1; Fig. 3). A significant
difference between baseline and day 7 and/or day 14 was found in
4 groupswith logCFU, in 5 groupswith TTP, and in 2 groupswith
CT. The real test for discrimination between treatment effects at
day 7 and day 14 is shown in Table 2. One-way ANOVA delivered
the greatest F values for TTP, indicating that liquid culture had the
most favorable ratio of within-group to between-group variation
to discriminate between groups for treatment effects at day 7 and
day 14. Log CFU from solid culture medium displayed acceptable
discriminatory ability, while quantitative PCR, represented by
Xpert CT, was relatively poor.
DISCUSSION
This prospective study directly compared three different methods
for the quantification of the mycobacterial load in sputum speci-
mens collected 7 and 14 days after initiation of antituberculosis
treatment. All three methods were able to demonstrate an average


































FIG 2 Individual activities of log CFU, TTP, and CT from day 0 to day 14 are plotted against each other. A strong correlation was found between log CFU and
TTP (rho0.726; P 0.0001), and a moderate correlation was found between log CFU and CT (rho0.385; P 0.0017) and TTP and CT (rho 0.400;
P 0.0004).
TABLE 1 Treatment effects measured with log CFU, TTP, and CT
a
Measurement Group
Baseline Days 0–7 Days 0–14
n Value n Change in value P n Change in value P
Log CFU Group 1 14 5.51 (1.15) 11 0.94 (1.76) 0.096 12 0.97 (1.35) 0.018
Group 2 15 5.91 (0.77) 14 0.32 (1.18) 0.429 13 0.97 (0.72) 0.009
Group 3 14 5.42 (0.97) 13 0.47 (1.41) 0.434 12 0.17 (1.41) 0.994
Group 4 14 5.48 (0.91) 12 0.19 (0.56) 0.367 12 0.39 (0.76) 0.385
Group 5 13 6.34 (0.79) 12 1.17 (0.82) 0.004 10 1.84 (1.03) 0.0006
Group 6 13 5.67 (1.17) 13 0.08 (0.47) 0.860 12 0.28 (0.71) 0.384
Total 83 5.72 (1.00) 75 0.26 (1.23) 0.2112 71 0.55 (1.24) 0.0006
TTP Group 1 15 115.6 (39.4) 15 83.7 (73.7) 0.0005 15 91.5 (77.5) 0.0001
Group 2 15 100.0 (20.6) 15 53.7 (40.6) 0.0002 15 78.1 (54.5) 0.0001
Group 3 15 120.4 (56.0) 14 10.6 (62.2) 0.607 12 6.68 (36.7) 0.835
Group 4 15 125.7 (42.4) 15 2.13 (23.2) 0.897 15 11.3 (24.9) 0.423
Group 5 15 124.3 (77.4) 14 70.5 (50.9) 0.073 13 151.1 (125.1) 0.004
Group 6 15 110.1 (24.5) 15 2.52 (21.9) 0.770 14 13.2 (41.0) 0.365
Total 90 116.0 (47.6) 88 35.5 (59.3) 0.0002 84 54.8 (86.8) 0.0001
CT Group 1 14 19.1 (4.57) 11 2.33 (2.80) 0.331 14 3.87 (5.75) 0.030
Group 2 14 18.9 (3.81) 12 1.06 (3.18) 0.476 15 1.27 (3.32) 0.311
Group 3 14 19.6 (3.54) 10 0.92 (2.71) 0.181 12 0.61 (3.86) 0.478
Group 4 14 20.1 (4.45) 14 0.77 (2.18) 0.628 14 1.29 (3.60) 0.524
Group 5 13 17.9 (3.27) 12 0.91 (3.72) 0.425 11 3.56 (2.63) 0.021
Group 6 14 20.0 (3.34) 14 0.87 (3.05) 0.277 15 1.85 (5.58) 0.350
Total 83 19.3 (3.88) 73 0.55 (3.07) 0.6030 81 2.06 (4.37) 0.0020
a Baseline values are means standard deviations. All P values were calculated using unpaired Student’s t test. n, number of patients with measurements.
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decrease of the mycobacterial sputum load. TTP in liquid culture
detected treatment effects earlier and more frequently than the
other methods, and it discriminated best between treatment
groups. CFU counting on agar plates was comparable to TTP.
Both culture-based methods had discriminatory power that was
clearly superior to that of real-time PCR.
Why does PCR in the form of standardized Xpert CT perform
so poorly in the detection of early treatment effects? This can be
explained by the ability of Xpert to detect DNA from whole but
metabolically inactive or dead bacteria or even free DNA causing
false-positive signals. For establishing the diagnosis of tuberculo-
sis, a high sensitivity is an advantage because the presence of my-
cobacterial DNA in sputum is associated with disease, and it does
not matter whether the DNA detected comes from viable or dead
bacteria. For monitoring of treatment effects, however, the dis-
tinction between DNA contained in viable mycobacteria and
DNA originating from other sources becomes critical, because
bacteria killed by antituberculosis treatment are subsequently ex-
pectorated in sputum, and it is known that mycobacterial DNA
survives for an extended period (15). This does not encourage the
hope that Xpert could emerge as a treatment-monitoring tool for
the HIV-positive, smear-negative tuberculosis patients frequently
encountered in countries such as South Africa. A modified proto-
col for Xpert intended to exclude DNA from nonviable mycobac-
teria from the reaction could remedy this problem, and research in
this area is ongoing (16).
The analysis reported here is based on a single study of only 14
days’ duration with only 4 time points assayed. We are confident,
however, that the results are valid, since TTP andCTwere similarly
well correlated in a previous study at our laboratory with 74 spu-
tum samples collected before treatment (rho  0.539; present
study, rho  0.632) (13). Also, merged data from five different
EBA studies revealed very similar correlations between 7-day
treatment activities determined by TTP and log CFU (rho 
0.649; present study, rho0.673) (4).
In conclusion, our results demonstrate that culture-based
methods remain the standard formeasuring the decline of sputum
bacterial load during the early phase of antituberculosis treat-
ment. The Xpert’s easy handling and quick results do not com-
pensate for its low discriminatory power between groups with
different treatments. Measures that reduce contamination with
DNA from nonviable bacteria might transform the value of this
technique.
ACKNOWLEDGMENTS
We thank all patients for participation in this study and the staff from the
Centre of Clinical Tuberculosis Research (CCTR) for technical assistance.
This studywas conducted as an activity of the PanAfricanConsortium for
the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). PanACEA is
funded by EDCTP grants CT.2004.32011.001, IP.2007.32011.011,
IP.2007.32011.012, and IP.2007.32011.013, the Bill and Melinda Gates
Foundation, the UKMedical Research Council, and the GermanMinistry
of Science and Technology (BmBF; grant 01KA0901). A specific Ph.D.
stipend was given by PanACEA to X. A. Kayigire to foster local career
development.
The Pan African Consortium for the Evaluation of Anti-tuberculosis
Antibiotics (PanACEA) comprises the following individuals and institu-
tions: Medical Centre of the University of Munich, Munich, Germany
(Sonja Henne and Anna Maria Mekota, Norbert Heinrich, Andrea Ra-
chow, Anke Kohlenberg, Elmar Saathoff, and Michael Hoelscher); Uni-
versity of St. Andrews, St Andrews, United Kingdom (Stephen Gillespie);
Radboud University Nijmegen Medical Centre, Nijmegen, the Nether-
lands (Georgette Plemper van Balen, Marloes Weijers, Rob Aarnoutse,
andMartin Boeree);UniversityCollege of London, London,UnitedKing-











































































































FIG 3 The mean change from baseline (SDs are shown as vertical bars) of log CFU, TTP, and CT after 7 and 14 days of treatment is shown for all six groups.
Significantly differentmeasurements for days 0 to 7 or days 0 to 14were found for TTP in 2 and 3, for logCFU in 1 and 3, and forCT in 0 and 2 groups, respectively.
Statistically significant differences between time points are indicated by asterisks (* P 0.05, ** P 0.001, *** P 0.0001, BL baseline, D7 day 7,
D14 day 14).
TABLE 2 Discrimination between treatment effectsa
Activity period
Log CFU TTP CT
F P F P F P
Days 0 to 7 4.135 0.0024 9.012 0.0001 1.995 0.0910
Days 0 to 14 7.277 0.0001 11.58 0.0001 1.203 0.3160
a One-way ANOVA was used for treatment activities over 7 days and 14 days measured
with log CFU, TTP, and CT. Greater F values represent a better ability to discriminate
between groups for treatment effects (there were 6 treatment groups for each period).
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